TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15635344
Drug: Plant sterols/stanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols/stanols (2 g/day) incorporated into margarine (25 g/day)
Study: 1092514
Drug: Theophylline (7.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (7.3 mg/kg per dose administered every 6 hr)
Study: 1092514
Drug: Ephedrine (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (alone or in combination with theophylline and hydroxyzine)
Study: 30773497
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg daily
Study: 22882740
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (1.53 g EPA and 0.31 g DHA per 1000 kcal ME)
Study: 22882740
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil supplementation (0.00 g EPA and 0.00 g DHA per 1000 kcal ME)
Study: 11061244
Drug: Anticonvulsant sodium
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant sodium channel blockers
Study: 11061244
Drug: Gabapentin (anticonvulsant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (anticonvulsant calcium channel blocker)
Study: 11061244
Drug: Tramadol (mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (mixed opioid and monoaminergic drug)
Study: 11061244
Drug: Dextromethorphan (NMDA-antagonist)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (NMDA-antagonist)
Study: 11061244
Drug: Mexiletine (antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (antiarrhythmic sodium channel blocker)
Study: 8356370
Drug: Manual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual treatment with steroid injections
Study: 8356370
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (standardized conventional but optimized activating treatment)
Study: 29665493
Drug: Daily positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily positive events
Study: 29665493
Drug: Daily stressful
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily stressful events
Study: 27316778
Drug: 1% Tenofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Tenofovir Gel
Study: 25190226
Drug: Alogliptin and
Normalized name: Alogliptin and Pioglitazone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin and insulin
Study: 25190226
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and insulin
Study: 21308859
Drug: 6-day residential
Normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-day residential course of lectures, discussions and peer groups on issues related to treatment and living with cancer
Study: 16424293
Drug: Oxandrolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (10 mg twice daily)
Study: 12001541
Drug: Intravenous heparin/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin/oral phenprocoumon
Study: 31952249
Drug: Synbiotic supplement
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplement containing Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium bifidum, and a galactooligosaccharide mixture; duration: 3 months.
Study: 31952249
Drug: Synbiotic supplement;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic supplement;
Study: 29941151
Drug: ZX008 (fenfluramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX008 (fenfluramine hydrochloride oral solution) 0.8 mg/kg after a 10-hour overnight fast
Study: 29941151
Drug: ZX008 (fenfluramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX008 (fenfluramine hydrochloride oral solution) 0.8 mg/kg 30 minutes after a high-fat breakfast
Study: 25756831
Drug: FDC aclidinium
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC aclidinium 400 μg/formoterol 12 μg (ACL400/FOR12 FDC)
Study: 25756831
Drug: FDC aclidinium
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC aclidinium 400 μg/formoterol 6 μg (ACL400/FOR6 FDC)
Study: 19723906
Drug: DMARD adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD adherence measured by Medication Adherence Scale (MARS)
Study: 19723906
Drug: Disease duration,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease duration, perceived side-effects, beliefs about necessity of medicine
Study: 17703139
Drug: Furosemide or
Normalized name: furosemide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide or HCTZ administered alone
Study: 15385638
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium intake (<5 g/day)
Study: 15385638
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium intake (100 mg/kg/day)
Study: 7886394
Drug: Omeprazole plus
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole plus amoxicillin (40 mg or 80 mg) for 1- or 2-week regimens
Study: 7886394
Drug: Omeprazole plus
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole plus amoxicillin
Study: 20090337
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg) once daily for 6-8 weeks before H. pylori eradication (group A)
Study: 20090337
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment followed by lansoprazole (30 mg) for 6-8 weeks (group B)
Study: 18381181
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg by mouth, 3 times per day for 4 weeks)
Study: 10393676
Drug: Aspirin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (250 mg/d)
Study: 26538208
Drug: Mirtazapine 15
Normalized name: mirtazapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 15 mg daily for 8 weeks
Study: 19190916
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg hyoscine N‐butylbromide (HBB)
Study: 2666139
Drug: SR‐Nicardipine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR‐Nicardipine 40 mg b.d.
Study: 29548285
Drug: Pf-PQ1 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pf-PQ1 (0.25 mg/kg primaquine)
Study: 29548285
Drug: Pv-PQ14 (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pv-PQ14 (14 days unsupervised 3.5 mg/kg primaquine)
Study: 27815344
Drug: SVG-DES (Drug-Eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVG-DES (Drug-Eluting Stents)
Study: 20297945
Drug: Disulfiram 800
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram 800 mg twice a week for 26 weeks
Study: 18355302
Drug: Gender, absolute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender, absolute levodopa dose, weight, disease duration, and initial motor Unified Parkinson's disease rating score
Study: 1521875
Drug: Prednisolone 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 0.8 mg/kg
Study: 29584548
Drug: Obinutuzumab (GA101)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (GA101) plus Bendamustine (B); G 1,000 mg (days 1, 8, and 15, cycle 1; day 1, cycles 2 to 6) plus B 90 mg/m2/d (days 1 and 2, all cycles); G maintenance (1,000 mg every 2 months) for up to 2 years.
Study: 29584548
Drug: Bendamustine monotherapy;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine monotherapy; B 120 mg/m2/d.
Study: 24417786
Drug: CG100649 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG100649 6 mg
Study: 24417786
Drug: CG100649 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG100649 6 mg + ketoconazole 400 mg
Study: 23046564
Drug: 2.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/day of n-3 PUFA for 8 weeks
Study: 17141978
Drug: Subcutaneous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous amifostine 500 mg (two 250-mg injections) before radiation therapy
Study: 12147537
Drug: Patients requiring
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients requiring vasopressor agents
Study: 7726267
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg single oral dose
Study: 7482105
Drug: Clotrimazole 100
Normalized name: clotrimazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 100 mg vaginal suppository twice a day for 3 days
Study: 2373576
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/kg caffeine)
Study: 7353458
Drug: ID glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID glucose, 30-100 g (600-2000 ml/hr, 5% D/W)
Study: 7353458
Drug: IV normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV normal saline (200 ml/hr and 1000 ml/hr)
Study: 7353458
Drug: IV glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV glucose, 10 g (200 ml/hr, 5% D/W)
Study: 7353458
Drug: IV glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV glucose, 25 g (250 ml/hr, 10% D/W)
Study: 7353458
Drug: IV glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV glucose, 100 g (1000 ml/hr, 10% D/W)
Study: 7353458
Drug: ID normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID normal saline (1000 ml/hr)
Study: 29484510
Drug: Quranic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quranic therapy sessions
Study: 22879453
Drug: Protein-energy supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-energy supplementation (two 200-mL cans of commercial liquid formula providing additional 400 kcal of energy, 25g of protein, 9.4g of essential amino acids, 400mL of water) per day for 12 weeks
Study: 17100983
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg alone
Study: 17100983
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg with naproxen 500 mg
Study: 17100983
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg alone
Study: 17100983
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg alone and with naproxen 500 mg
Study: 15201942
Drug: 1 mg/Kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/Kg/day IL-1ra in combination with methotrexate (MTX)
Study: 15201942
Drug: IL-1ra (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1ra (various dosages: 30, 75, and 150 mg/day)
Study: 8266382
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for systolic hypertension
Study: 27020278
Drug: Ampicillin-Cloxacillin combination
Normalized name: ampicillin / cloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-Cloxacillin combination alone
Study: 27020278
Drug: Ampicillin-Cloxacillin combination
Normalized name: ampicillin / cloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-Cloxacillin combination with quinine
Study: 27020278
Drug: Antibiotics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics with quinine
Study: 19918248
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein with isoflavones (15 g soy protein and 100 mg isoflavones)
Study: 12536506
Drug: Lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupus anticoagulant (LA) positive
Study: 9403579
Drug: Estrogen supplementation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen supplementation (estradiol valerate, 2 mg daily, n=7)
Study: 31915153
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg (n = 26)
Study: 31915153
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg (n = 26) under glucose clamp conditions
Study: 31915153
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg (n = 26) under pancreatic clamp conditions
Study: 23157937
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of dialysis (GFR 10-14 mL/min/1.73 m²)
Study: 23157937
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of dialysis (GFR 5-7 mL/min/1.73 m²)
Study: 21600709
Drug: Conventional Treatment
Normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Treatment Model (CTM)
Study: 18424975
Drug: Microsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical treatment for galenic DAVF using posterior interhemispheric approach
Study: 18424975
Drug: Microsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical treatment for straight sinus DAVF using supracerebellar-infratentorial approach
Study: 18424975
Drug: Microsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical treatment for torcular DAVF using torcular craniotomy
Study: 18424975
Drug: Microsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical treatment for tentorial sinus DAVF using supratentorial-infraoccipital approach
Study: 18424975
Drug: Microsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical treatment for superior petrosal sinus DAVF using extended retrosigmoid approach
Study: 18424975
Drug: Microsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical treatment for incisural DAVF using pterional or subtemporal approach
Study: 16585302
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis antigens)
Study: 16585302
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td vaccine (control)
Study: 11523062
Drug: Enalapril suspension
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril suspension (10 mg)
Study: 11523062
Drug: VASOTEC tablets
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VASOTEC tablets (10 mg)
Study: 9190554
Drug: 150 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/kg/day of cephradine divided in four doses
Study: 9190554
Drug: 40 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg/day in four doses of clindamycin
Study: 31429705
Drug: MC4R variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC4R variant rs12970134 (A/G)
Study: 28107288
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with 1.0 g/L 2'fucosyllactose (2'FL) and 0.5 g/L lacto‐N‐neotetraose (LNnT)
Study: 26571496
Drug: Lapatinib 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1000 mg once daily (QD)
Study: 26571496
Drug: Lapatinib 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1500 mg once daily (QD)
Study: 26571496
Drug: Lapatinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 500 mg twice daily (BID)
Study: 26571496
Drug: Lapatinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (various doses)
Study: 21792527
Drug: Creatine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (3 g)
Study: 21792527
Drug: Glibenclamide (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (3.5 mg)
Study: 18625084
Drug: Randomized trials
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized trials of psychological therapies
Study: 18625084
Drug: Practice-based studies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice-based studies of psychological therapies
Study: 12884461
Drug: Aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminolevulinic acid pre-treatment with Blu-U light
Study: 10589636
Drug: Fentanyl 4
Normalized name: fentanyl 400 MCG Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 4 microg/mL
Study: 10589636
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of levobupivacaine 0.125% and fentanyl 4 microg/mL
Study: 7036764
Drug: Sulfadoxine-pyrimethamine combined
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine combined with chloroquine (10 mg/kg)
Study: 26694596
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose omega-3 fish oil (4.5 g eicosapentaenoic acid and docosahexaenoic acid daily)
Study: 26694596
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose omega-3 fish oil (0.45 g/day)
Study: 25212703
Drug: Daclizumab HYP
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab HYP (50, 150, or 300 mg subcutaneous; 100 or 200 mg biweekly subcutaneous with a 200 mg loading dose; 200 or 400 mg intravenous)
Study: 21505898
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg orally qid on days 2-5 plus standard antiemetics (ondansetron 8 mg orally bid on days 2-5 and dexamethasone 8 mg orally bid on days 2-4)
Study: 21505898
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard antiemetics (ondansetron 8 mg orally bid on days 2-5 and dexamethasone 8 mg orally bid on days 2-4)
Study: 19204202
Drug: Oral uracil-tegafur
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral uracil-tegafur (UFT) for 2 years
Study: 17713157
Drug: CPG 10101
Normalized name: CPG 10101
DrugBank: CPG 10101 (DB05530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG 10101 (ACTILON) 0.25 to 20 mg administered subcutaneously, twice, 14 days apart; 4 mg administered twice weekly for four weeks
Study: 11555846
Drug: Gln27Glu beta(2)-adrenergic
Normalized name: beta-Arbutin
DrugBank: Arbutin (DB11217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gln27Glu beta(2)-adrenergic receptor variant
Study: 11555846
Drug: Pro12Ala peroxisome
Normalized name: (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)SULFANYL)-2-METHYLPHENOXY)ACETIC ACID PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) AGONIST,ANTIHYPERLIPIDAEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro12Ala peroxisome proliferator-activated receptor gamma variant
Study: 9758732
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of methylprednisolone intravenously upon induction of anesthesia
Study: 7887827
Drug: Heparin-coated membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated membrane oxygenator (Group H)
Study: 28603098
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg per day)
Study: 28603098
Drug: Silymarin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (5 mg/kg per day)
Study: 23812513
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream with breastfeeding (EB group)
Study: 23812513
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream with oral distilled water (EW group)
Study: 23812513
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream with oral distilled water (PCW group)
Study: 30897464
Drug: Positive Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Cognitive Behavior Therapy (P-CBT)
Study: 30897464
Drug: Traditional Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Cognitive Behavior Therapy (T-CBT)
Study: 30897464
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (P-CBT and T-CBT)
Study: 30676635
Drug: Aflibercept 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2.0 mg (201 eyes)
Study: 30676635
Drug: Bevacizumab 1.25
Normalized name: Bevacizumab 1.25mg/0.05mL Intraocular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 1.25 mg (185 eyes)
Study: 30676635
Drug: Ranibizumab 0.3
Normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3 mg (192 eyes)
Study: 23467003
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl (on a background of standard therapy, including RAAS inhibitors)
Study: 17079637
Drug: Nalbuphine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 50 microg x kg(-1) iv (max 5 mg)
Study: 11149991
Drug: Active heat-steam
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active heat-steam treatment of homes
Study: 11149991
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (group 3)
Study: 7826909
Drug: Paclitaxel (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (125 mg/m2 over 24 hours)
Study: 7826909
Drug: Paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135 mg/m2 over 3 hours)
Study: 29953876
Drug: 24 g
Normalized name: glucose 24 g/31 g oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g inulin (0.5 g U-13C-inulin)
Study: 29953876
Drug: 24 g
Normalized name: glucose 24 g/31 g oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g maltodextrin placebo
Study: 26639952
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy